ECSP024404A - Ligandos para receptores de melanocortina - Google Patents

Ligandos para receptores de melanocortina

Info

Publication number
ECSP024404A
ECSP024404A EC2002004404A ECSP024404A ECSP024404A EC SP024404 A ECSP024404 A EC SP024404A EC 2002004404 A EC2002004404 A EC 2002004404A EC SP024404 A ECSP024404 A EC SP024404A EC SP024404 A ECSP024404 A EC SP024404A
Authority
EC
Ecuador
Prior art keywords
ligands
melanocortine
receptors
melanocortine receptors
het
Prior art date
Application number
EC2002004404A
Other languages
English (en)
Inventor
Philip Albert Carpino
Bradley Paul Morgan
Bridget Mccarthy Cole
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP024404A publication Critical patent/ECSP024404A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un compuesto de la fórmula. En la que R3, R4, R6, R7, X4, Q y HET son como se han definido anteriormente, útiles para el tratamiento o la prevención de trastornos, enfermedades o procesos sensibles a la activación del receptor de melanocortina.
EC2002004404A 2000-06-28 2002-12-26 Ligandos para receptores de melanocortina ECSP024404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21461600P 2000-06-28 2000-06-28

Publications (1)

Publication Number Publication Date
ECSP024404A true ECSP024404A (es) 2003-02-06

Family

ID=22799775

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004404A ECSP024404A (es) 2000-06-28 2002-12-26 Ligandos para receptores de melanocortina

Country Status (26)

Country Link
US (1) US20020072604A1 (es)
EP (1) EP1294719A1 (es)
JP (1) JP2004501917A (es)
KR (1) KR20030017571A (es)
CN (1) CN1440406A (es)
AP (1) AP2001002196A0 (es)
AR (1) AR030301A1 (es)
AU (1) AU2001260548A1 (es)
BG (1) BG107268A (es)
BR (1) BR0111567A (es)
CA (1) CA2412563A1 (es)
EA (1) EA200201119A1 (es)
EC (1) ECSP024404A (es)
IL (1) IL152781A0 (es)
IS (1) IS6617A (es)
MA (1) MA26920A1 (es)
MX (1) MXPA03000063A (es)
NO (1) NO20026280D0 (es)
OA (1) OA12296A (es)
PA (1) PA8521501A1 (es)
PE (1) PE20020208A1 (es)
PL (1) PL360855A1 (es)
TN (1) TNSN01097A1 (es)
UY (1) UY26804A1 (es)
WO (1) WO2002000654A1 (es)
ZA (1) ZA200210277B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264977B2 (en) * 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
CA2515717A1 (en) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
EP1661898A4 (en) 2003-08-29 2009-04-15 Takeda Pharmaceutical BICYCLIC PIPERAZINE COMPOUND AND ITS USE
JP2005306839A (ja) * 2003-08-29 2005-11-04 Takeda Chem Ind Ltd 二環性ピペラジン化合物およびその用途
KR101092716B1 (ko) * 2004-04-08 2011-12-09 아스테라스 세이야쿠 가부시키가이샤 화합물 ws727713
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
KR100997177B1 (ko) * 2005-07-08 2010-11-29 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
EP2039695A4 (en) * 2006-07-11 2010-09-15 Takeda Pharmaceutical BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0716436B8 (pt) 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
EP2148692B1 (en) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
EP4714953A1 (en) * 2023-05-16 2026-03-25 Scohia Pharma, Inc. Melanocortin 2-type receptor antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055679A1 (en) * 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
WO1999064002A1 (en) * 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) * 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
US20020072604A1 (en) 2002-06-13
MXPA03000063A (es) 2003-09-25
WO2002000654A1 (en) 2002-01-03
IL152781A0 (en) 2003-06-24
NO20026280L (no) 2002-12-30
IS6617A (is) 2002-11-14
PE20020208A1 (es) 2002-03-13
NO20026280D0 (no) 2002-12-30
OA12296A (en) 2006-05-12
CN1440406A (zh) 2003-09-03
PL360855A1 (en) 2004-09-20
AP2001002196A0 (en) 2002-12-21
KR20030017571A (ko) 2003-03-03
CA2412563A1 (en) 2002-01-03
JP2004501917A (ja) 2004-01-22
EP1294719A1 (en) 2003-03-26
UY26804A1 (es) 2002-01-31
AR030301A1 (es) 2003-08-20
PA8521501A1 (es) 2002-10-24
BR0111567A (pt) 2003-05-06
TNSN01097A1 (fr) 2005-11-10
EA200201119A1 (ru) 2003-06-26
AU2001260548A1 (en) 2002-01-08
BG107268A (en) 2003-06-30
ZA200210277B (en) 2003-12-19
MA26920A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
UY26804A1 (es) Ligandos para receptores de melanocortina
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
CY1112516T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης και οι χρησεις τους
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
BG108495A (en) 5-ht receptor ligands and uses thereof
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
UY28150A1 (es) Agentes terapeuticos
NI200700156A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurológicos
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
CR8759A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores quimioquinas
CR8775A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
DE60129154D1 (de) Neuartige verbindungen
MA30485B1 (fr) Aminothiazoles et leurs utilisations
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
NO20072060L (no) 2-acylaminotiazolderivater
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.